Document:

Assignment and Assumption Agreement

 

EXHIBIT 10.1

ASSIGNMENT AND ASSUMPTION OF MEMBERSHIP 

INTEREST IN PRODECO TECHNOLOGIES, LLC

SEPARATE FROM CERTIFICATE

FOR VALUE RECEIVED in the sum of $30,000.00, the undersigned, A BETTER BIKE, LLC and EBIKE, LLC, (the "Assignor"), hereby grants, bargains, sells, assigns and transfers to TAVONE FAMILY HOLDINGS, LLC, a Florida limited liability company organized under the laws of the State of Florida (the "Assignee"), and Assignee hereby accepts and assumes, all of Assignor's right, title and interest in and to the LLC Interest (as defined below), and Assignor does hereby irrevocably constitute and appoint any manager or officer of the Company (as defined below) as attorney-in-fact to transfer said LLC Interest on the books of the Company with full power of substitution in the premises.

For purposes hereof, the term "LLC Interest" means all of the Assignor's right, title and interest in Assignor's 100% of the issued and outstanding membership interests (4,850,000 membership units, collectively) in PRODECO TECHNOLOGIES, LLC, a Florida limited liability company (the "Company"), including, but not limited to, (i) all the profits, losses, items in the nature of income, gain, credit, expense or loss, and the surplus and/or distributions allocable to Assignor in respect of such interest accruing after the date hereof; (ii) Assignor's rights, powers, obligations and benefits as a member of the Company in respect of such interest; and (iii) any other right, title and interest attributable to Assignor under the Operating Agreement of the Company and any other agreement relating to the Company, the Limited Liability Company Act of the State of Florida or any other applicable law in respect of such interest. Assignor represents and warrants to Assignee that it is the only legal, record and beneficial owner of the LLC Interest and that the LLC Interest is free and clear of all liens, pledges, security interests, irrevocable proxies, encumbrances or restrictions.

By executing below, Assignor hereby agrees to: (i) be bound by the provisions, terms and conditions of the Amended and Restated Operating Agreement of the Company and any other agreement relating to the Company, the Limited Liability Company Act of the State of Florida or any other applicable law in respect of the LLC Interest; in particular, the following provision:

"Each Member agrees and acknowledges that, at any time they are a Member of the Company and for a period of three (3) years after their termination as a Member of the Company, they will not, directly or indirectly, as principal, partner, joint venture, shareholder, investor, owner, employer, employee, officer, director, consultant or otherwise, own, manage, operate, finance, control, engage in, consult with or otherwise participate in the ownership, management, operation, research, development, financing or control of, any business activity deemed a "Competitive Business" anywhere. A "Competitive Business" is one that is engaged in the business of development, manufacture or retail sale of electric powered bicycles, electric skateboards/hoverboards, roller skates, aerial drones, paddle boards and other similar outdoor recreational products; (b) directly or indirectly induce any employee of the Company to terminate or negatively

-1-

 

alter his or her relationship with the Company or (c) solicit the business of any client or customer of the Company (other than on behalf of the Company) or (d) induce any supplier, vendor, consultant or independent contractor of the Company to terminate or negatively alter his, her or its relationship with the Company."

(ii) release Assignor, together with all officers, directors, employees and agents of Assignor ("Assignor Related Parties"), from all obligations, claims, causes of action and liabilities relating, directly or indirectly, to the Company, the LLC Interest, the Amended Operating Agreement of the Company and any other agreement relating to the Company and the assignment ("Claims") arising on or prior to the date hereof from a third party; and (iii) indemnify, defend and hold harmless the Assignor Related Parties from and against all Claims subsequent to the assignment. Assignor has assigned its rights to the proceeds from this sale to Paymeon, Inc., which shall receive the payment provided for hereinabove.

Signature page to follow - this document may be executed in counterparts

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

-2-

 

WITNESS OUR HANDS AND SEALS AS OF THIS 18 DAY OF November, 2016

		
	 
	ASSIGNOR: EBIKE, LLC

	 
	 

	 
	

	 
	 

	 
	ASSIGNOR: A BETTER BIKE, LLC

	 
	 

	 
	 

	 
	

	 
	 

	 
	ASSIGNEE: TAVONE FAMILY HOLDINGS, LLC

	 
	 

	 
	 

	 
	

-3-Exhibit

Exhibit 10.1

November 21, 2016

Martin Koller, M.D.

Re:    Retirement Transition

Marty,

This letter confirms the following in connection with your decision to retire from Prothena Biosciences Inc (the “Company”):

		
	1.
	We have requested that you continue to serve as Chief Medical Officer of Prothena Corporation plc and continue your employment with the Company until we hire and appoint a new Chief Medical Officer.  You have agreed to do so.

		
	2.
	We have requested that you continue your employment with the Company after a new Chief Medical Officer is hired and appointed until December 31, 2017 (the “Transition Period”), to assist with the transition of your responsibilities and other matters as requested by your replacement or me.  During the first three months of the Transition Period, we have asked that you remain a full-time employee; thereafter until December 31, 2017, we have asked that you remain as a part-time employee regularly working no less than 30 hours per week.  You have agreed to do so.

		
	3.
	For so long as you continue to serve as Chief Medical Officer, you will continue to receive the same compensation and participate in the same compensation and benefit plans and arrangements that you currently receive and in which you currently participate; provided that you will not be eligible to receive a bonus for 2017.

		
	4.
	During the portion of the Transition Period that you remain a full-time employee, you will continue to be paid a salary at your current annual salary rate of $371,315.  During the portion of the Transition Period that you remain a part-time employee, you will be paid a salary at an annual salary rate of $278,486.  While you remain an employee, you will continue to be eligible to participate in benefit plans and arrangements generally available to other full-time or part-time employees (as the case may be); provided that you will not be eligible to receive a cash bonus for 2017.  Stock options previously granted to you will continue to vest in accordance with their terms while you remain an employee.  In according with their terms, any options that are unvested on the date that you cease employment with the Company will immediately terminate, and any options that are vested on that date will remain outstanding until the three-month anniversary of the date your employment ends.

Your employment continues to be “at will.”  This means that you and Prothena each have the right to terminate the employment relationship at any time, with or without cause.  Nothing in this letter should be taken as a guarantee of continued employment or a specific term of employment.

Prothena Biosciences Inc
650 Gateway Boulevard
South San Francisco, CA 94010 U.S.A.

You also agree that your decision to retire at the end of the Transition Period does not constitute a Triggering Event under the Company’s Severance Plan (as such term is defined therein) and does not constitute an Involuntary Termination under your Option Award Agreements (as such term is defined therein).

By signing this letter, you acknowledge that it sets out our entire agreement between you and the Company and supersedes all prior oral and written agreements, understandings, commitments and practices regarding the subject of this letter.  No amendments to this agreement may be made except in writing signed by a duly authorized representative of the Company.

If this letter accurately describes the circumstances of and your arrangement as you transition to retirement, please sign this letter and return it to me by November 22, 2016.

We thank you for your willingness to continue to provide services to Prothena as you transition to retirement.

Best regards,

/s/ Gene G. Kinney

Gene G. Kinney, Ph.D.
President and Chief Executive Officer

Acknowledged and Agreed:

     /s/ Martin Koller     
Martin Koller, M.D.
Date: November 21, 2016

2SEC Connect

 

Exhibit
4.01

CERTIFICATE
OF

AMENDED
AND RESTATED ARTICLES OF INCORPORATION

OF

INNOVUS
PHARMACEUTICALS, INC.

Pursuant to the
provisions of Nevada Revised Statutes 78.390 and 78.403, the
undersigned officer of Innovus Pharmaceuticals, Inc., a Nevada
corporation, does hereby certify as follows:

A.           The
board of directors of the corporation has duly adopted resolutions
proposing to amend and restate the articles of incorporation of the
corporation as set forth below, declaring such amendment and
restatement to be advisable and in the best interests of the
corporation.

B.           The
amendment and restatement of the articles of incorporation as set
forth below has been approved by at least a majority of the voting
power of the stockholders of the corporation, which is sufficient
for approval thereof.

C.           This
certificate sets forth the text of the articles of incorporation of
the corporation as amended and restated in their entirety to this
date as follows:

 

AMENDED
AND RESTATED ARTICLES OF INCORPORATION

OF

INNOVUS
PHARMACEUTICALS, INC.

 
ARTICLE I

NAME

 

The
name of the corporation is Innovus Pharmaceuticals, Inc. (the
“Corporation”).

 
ARTICLE
II

REGISTERED
OFFICE

The
Corporation may, from time to time, in the manner provided by law,
change the registered agent and registered office within the State
of Nevada. The Corporation may also maintain an office or offices
for the conduct of its business, either within or without the State
of Nevada.

 
ARTICLE III

PURPOSE

The
Corporation is formed for the purpose of engaging in any lawful
activity for which corporations may be organized under the laws of
the State of Nevada.

 

 

 

ARTICLE IV

AUTHORIZED CAPITAL
STOCK

The
total authorized capital stock of the Corporation consists of three
hundred million (300,000,000) shares of capital stock, par value
$0.001 per share, consisting of (a) two hundred ninety two million
five hundred thousand (292,500,000) shares of common stock, par
value $0.001 per share, and (b) seven million five hundred thousand
(7,500,000) shares of
preferred stock, par value $0.001 per share (“Preferred Stock”). The
board of directors of the Corporation is hereby vested, to the
fullest extent permitted under the Nevada Revised Statutes (the
“NRS”),
with the authority to designate from time to time, by duly adopted
resolution(s), one or more series of the Preferred Stock, to fix
the number of shares constituting such series and to prescribe the
voting powers, designations, preferences, qualifications,
limitations, restrictions and relative, participating, optional and
other rights of such series. Any such resolution prescribing a
series of Preferred Stock must include a distinguishing designation
for such series. Except as otherwise required by law, holders of
any series of Preferred Stock shall be entitled to only such voting
rights, if any, as shall expressly be granted thereto by these
Amended and Restated Articles of Incorporation (as the same may be
further amended from time to time, the “Articles of
Incorporation”), including the certificate of
designation relating to such series of Preferred Stock, or the NRS.
To the extent provided in the certificate of designation relating
to a series of Preferred Stock, the board of directors may increase
(but not above the total number of then authorized and undesignated
shares of Preferred Stock) or decrease (but not below the number of
shares of that series then outstanding) the number of shares of
such series.

 

ARTICLE V

DIRECTORS

The
board of directors of the Corporation shall be elected or appointed
in such manner as shall be provided in the bylaws of the
Corporation (as amended from time to time, the “Bylaws”). Except as
otherwise fixed or provided for pursuant to the provisions of the
Articles of Incorporation, including any certificate of designation
relating to any series of Preferred Stock, the number of directors
may be changed from time to time in the manner provided in the
Bylaws.

ARTICLE VI

INAPPLICABILITY OF
CERTAIN NEVADA STATUTES

Section
1.                      
Inapplicability of
Combinations with Interested Stockholders Statutes. At such
time, if any, as the Corporation becomes a “resident domestic
corporation” (as that term is defined in NRS 78.427), the
Corporation shall not be subject to, or governed by, any of the
provisions in NRS 78.411 to 78.444, inclusive, as amended from time
to time, or any successor statutes.

Section
2.                      
Inapplicability of
Acquisition of Controlling Interest Statutes. In accordance
with the provisions of NRS 78.378, the provisions of NRS 78.378 to
78.3793, inclusive, as amended from time to time, or any successor
statutes, relating to acquisitions of controlling interests in the
Corporation, shall not apply to the Corporation or to any
acquisition of any shares of the Corporation’s capital
stock.

ARTICLE VII

INDEMNIFICATION;
EXCULPATION

Section
1.                     
Payment of
Expenses. To the fullest extent permitted under the NRS
(including, without limitation, to the fullest extent permitted
under NRS 78.7502 and 78.751(3)) and other applicable law, the
Corporation shall indemnify directors and officers of the
Corporation in their respective capacities as such and in any and
all other capacities in which any of them serves at the request of
the Corporation. In addition to any other rights of indemnification
permitted by the laws of the State of Nevada or as may be provided
for by the Corporation in the Bylaws or by agreement, the expenses
of directors and officers incurred in defending a civil or criminal
action, suit or proceeding, involving alleged acts or omissions of
such director or officer in his or her capacity as a director or
officer of the Corporation, must be paid, by the Corporation or
through insurance purchased and maintained by the Corporation or
through other financial arrangements made by the Corporation, as
they are incurred and in advance of the final disposition of the
action, suit or proceeding, upon receipt of an undertaking
by or on behalf of the
director or officer to repay the amount if it is ultimately
determined by a court of competent jurisdiction that he or she is
not entitled to be indemnified by the Corporation.

 

 

 

 

Section
2.                      
Limitation on
Liability. The liability of directors and officers of the
Corporation shall be eliminated or limited to the fullest extent
permitted by the NRS. If the NRS are amended to further eliminate
or limit or authorize corporate action to further eliminate or
limit the liability of directors or officers, the liability of
directors and officers of the Corporation shall be eliminated or
limited to the fullest extent permitted by the NRS, as so amended
from time to time.

Section
3.                      
Repeal and
Conflicts. Any repeal or modification of Section 1 or Section 2 of Article VI approved by the
stockholders of the Corporation shall be prospective only, and
shall not adversely affect any limitation on the liability of a
director or officer of the Corporation existing as of the time of
such repeal or modification. In the event of any conflict between
Section 1 or
Section 2 of
Article VI and any
other provision of the Articles of Incorporation, the terms and
provisions of Section
1 and/or Section
2 of Article
VI shall control.

 

ARTICLE VIII

MISCELLANEOUS

Section
1.                      
Mandatory Forum. To
the fullest extent permitted by law, and unless the Corporation
consents in writing to the selection of an alternative forum, the
Eighth Judicial District Court of Clark County, Nevada, shall be
the sole and exclusive forum for any or all actions, suits or
proceedings, whether civil, administrative or investigative or that
asserts any claim or counterclaim (each, an “Action”): (a) brought in
the name or right of the Corporation or on its behalf; (b)
asserting a claim for breach of any fiduciary duty owed by any
director, officer, employee or agent of the Corporation to the
Corporation or the Corporation’s stockholders; (c) arising or
asserting a claim arising pursuant to any provision of NRS Chapters
78 or 92A or any provision of the Articles of Incorporation or
Bylaws; (d) to interpret, apply, enforce or determine the validity
of the Articles of Incorporation or Bylaws; or (e) asserting a
claim governed by the internal affairs doctrine. In the event that
the Eighth Judicial District Court of Clark County, Nevada does not
have jurisdiction over any such Action, then any other state
district court located in the State of Nevada shall be the sole and
exclusive forum for such Action. In the event that no state
district court in the State of Nevada has jurisdiction over any
such Action, then a federal court located within the State of
Nevada shall be the sole and exclusive forum for such
Action.

Section
2.                      
Severability. If
any provision or provisions of the Articles of Incorporation is
held to be invalid, illegal or unenforceable as applied to any
circumstance for any reason whatsoever: (a) the validity, legality
and enforceability of such provision(s) in any other circumstance
and of the remaining provisions of the Articles of
Incorporation(including, without limitation, each portion of any
paragraph of the Articles of Incorporation containing any such
provision held to be invalid, illegal or unenforceable that is not
itself held to be invalid, illegal or unenforceable) shall not in
any waybe affected or impaired thereby; and (b) to the fullest
extent possible, the provisions of the Articles of Incorporation
(including, without limitation, each such portion of any paragraph
of the Articles of Incorporation containing any such provision
heldto be invalid, illegal or unenforceable) shall be construed (i)
so as to permit the Corporation to protect its directors, officers,
employees and agents from personal liability in respect of their
good faith service or (ii) for the benefit of the Corporation to
the fullest extent permitted by law.

Section
3.                      
Deemed Notice and
Consent. To the fullest extent permitted by law, each and
every natural person, corporation, general or limited partnership,
limited liability company, joint venture, trust, association or any
other entity purchasing or otherwise acquiring any interest (of any
nature whatsoever) in any shares of the capital stock of the
Corporation shall be deemed, by reason of and from and after the
time of such purchase or other acquisition, to have notice of and
to have consented to all of the provisions of (a) the Articles of
Incorporation (including, without limitation, Section
1 of this Article and this Section
3), (b) the Bylaws and (c) any amendment to the Articles
of Incorporation or the Bylaws enacted or adopted in accordance
with the Articles of Incorporation, the Bylaws and applicable
law.

Section
4.                      
Amendments to
Bylaws. The authority to adopt, amend or repeal the Bylaws
or any provision thereof is hereby reserved exclusively to the
board of directors of the Corporation, and the stockholders of the
Corporation shall have no authority or right to adopt, amend or
repeal the Bylaws.

*            *            *            *

 

 

 

IN
WITNESS WHEREOF, I have executed this Certificate of Amended and
Restated Articles of Incorporation of Innovus Pharmaceuticals, Inc.
as of October 10, 2016.

 

 

	
 

	
 
/s/ Bassam
Damaj

 Name:  Bassam
Damaj

 Title:   
Chief Executive Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00264-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00264-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00264-of-00352.parquet"}]]